Janus kinase inhibitors – a role for the treatment of cutaneous T-cell lymphomas?
Despite increases in prevalence, many cutaneous T-cell lymphoma (CTCL) patients still lack effective and safe therapies for their disease. The most prevalent subtype, mycosis fungoides is usually managed with skin directed treatments in early stages, while advanced stages are often targeted with sys...
Saved in:
| Main Authors: | Sarah E. Packer, Patrick M. Brunner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/or.2025.1482866/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unraveling the role of chemokines in cutaneous T-cell lymphoma: expression levels at different stages
by: Alba Guglielmo, et al.
Published: (2025-08-01) -
Erythrodermic cutaneous T-cell lymphoma: Insights from a Kenyan perspective
by: Caroline Mutio, MBChB, et al.
Published: (2025-10-01) -
OX40–OX40L Axis in Cutaneous T-Cell Lymphomas: Pathogenic, Prognostic, and Potential Therapeutic Perspectives
by: Alba Guglielmo, et al.
Published: (2025-05-01) -
Clinical spectrum of indolent mycosis fungoides with a gamma‐delta (γδ) phenotype: a single institution review including therapy and outcomes
by: N. A. Ufkes, et al.
Published: (2025-03-01) -
Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review
by: Olimpia Wiciun, et al.
Published: (2025-05-01)